S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:IBB

iShares Biotechnology ETF (IBB) Price, Holdings, & News

$122.56
-0.49 (-0.40%)
(As of 09/22/2023 ET)
Compare
Today's Range
$122.51
▼
$123.42
50-Day Range
$122.56
▼
$131.47
52-Week Range
$113.37
▼
$138.74
Volume
1.25 million shs
Average Volume
1.29 million shs
Market Capitalization
$7.13 billion
Assets Under Management
$7.07 billion
Dividend Yield
0.27%
Net Expense Ratio
0.44%
ProfileChartDividendInstitutional OwnershipHeadlinesHoldingsOptions ChainSEC FilingsShort InterestSocial MediaRatings
IBB stock logo

About iShares Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

IBB Price History

IBB ETF News Headlines

September 24, 2023 | realmoney.thestreet.com
Biotech Got Whopped. But I've Got a Plan
September 20, 2023 | americanbankingnews.com
iShares Biotechnology ETF Sees Unusually Large Options Volume (NASDAQ:IBB)
September 24, 2023 | Stansberry Research (Ad)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
September 8, 2023 | theglobeandmail.com
This Biotech Stock Offers Innovative Growth at a Massive Discount
September 4, 2023 | investorplace.com
The 3 Best Biotech Stocks to Buy Now: September 2023
August 17, 2023 | msn.com
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
July 6, 2023 | finance.yahoo.com
IBB - iShares Biotechnology ETF
July 4, 2023 | baystreet.ca
Why I’m Buying This Biotech ETF Today
September 24, 2023 | Stansberry Research (Ad)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
June 21, 2023 | barrons.com
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap
See More Headlines
Receive IBB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
iShares
Fund Name
iShares Biotechnology ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:IBB
Inception Date
2/5/2001
Fund Manager
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
ICE Biotechnology Index (TR) (USD)
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
270

Fund Statistics

Assets Under Management
$7.07 billion
Average Daily Volume
$1.49 million
Discount/Premium
-0.01%

Administrator, Advisor and Custodian

Administrator
JPMorgan Chase Bank, N.A.
Advisor
BlackRock Fund Advisors
Custodian
JPMorgan Chase Bank, N.A.
Distributor
BlackRock Investments, LLC
Transfer Agent
JPMorgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Latour Trading

Options

Optionable
Optionable
Options Volume
963
Put Options
612
Call Options
351
Short Interest
10,140,000 shs

Miscellaneous

Outstanding Shares
58,150,000
Beta
0.81
Creation Unit
50,000
Creation Fee
$614.00
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

iShares Biotechnology ETF Expenses

TypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.44%0.57%0.53%0.47%0.50%
Other Expenses0.00%0.40%0.52%0.29%0.57%
Total Expense0.44%0.72%0.69%0.56%0.69%
Fee Waiver0.00%-0.51%-0.55%-0.22%-0.59%
Net Expense0.44%0.61%0.59%0.51%0.57%

iShares Biotechnology ETF (IBB) Holdings & Exposure

Top 10 IBB Holdings

IBB Sector Exposure

IBB Industry Exposure

Full Holdings Details

Key Executives

  • George G. C. Parker Ph.D.
    Independent Chairman of the Board of Trustees
  • Michael Arthur Latham
    President, Trustee
  • Jack Gee
    Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn
    Chief Operating Officer, Executive Vice President

  • Bio & Compensation - 
  • Amy Schioldager
    Executive Vice President
  • Ira P. Shapiro
    Vice President, Chief Legal Officer
  • Matt Tucker
    Vice President

  • Bio & Compensation - 
  • Eilleen M. Clavere
    Secretary
  • Cecilia H. Herbert
    Independent Trustee
  • Charles A. Hurty
    Independent Trustee

Similar ETFs

Institutional Ownership

View All Institutional Transactions













IBB ETF - Frequently Asked Questions

How have IBB shares performed in 2023?

iShares Biotechnology ETF's stock was trading at $131.29 at the beginning of 2023. Since then, IBB stock has decreased by 6.6% and is now trading at $122.56.
View the best growth stocks for 2023 here.

How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF?

iShares Biotechnology ETF declared a quarterly dividend on Tuesday, June 6th. Shareholders of record on Thursday, June 8th will be given a dividend of $0.0062 per share on Tuesday, June 13th. This represents a $0.02 dividend on an annualized basis and a yield of 0.02%. The ex-dividend date is Wednesday, June 7th.
Read our dividend analysis for IBB.

What does IBB invest in?

iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.07 billion assets under management.

What stocks does iShares Biotechnology ETF hold?

IBB invests in 270 holdings. Some of the stocks in their portfolio include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), IQVIA (IQV), Biogen (BIIB), Seagen (SGEN), Moderna (MRNA), Illumina (ILMN) and Mettler-Toledo International (MTD).

What is the management fee for iShares Biotechnology ETF?

iShares Biotechnology ETF's management fee is 0.44% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.44%.

When did iShares Biotechnology ETF's stock split?

iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were distributed to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What other stocks do shareholders of iShares Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).

What is iShares Biotechnology ETF's stock symbol?

iShares Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

Who are iShares Biotechnology ETF's major shareholders?

iShares Biotechnology ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (485.07%), Citigroup Inc. (4.04%), JPMorgan Chase & Co. (3.49%), Royal Bank of Canada (2.24%), Commerce Bank (1.23%) and Healthcare of Ontario Pension Plan Trust Fund (1.20%).

How do I buy shares of iShares Biotechnology ETF?

Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iShares Biotechnology ETF's stock price today?

One share of IBB stock can currently be purchased for approximately $122.56.

How much money does iShares Biotechnology ETF make?

iShares Biotechnology ETF (NASDAQ:IBB) has a market capitalization of $7.13 billion.

This page (NASDAQ:IBB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -